There is a pharmaceutical product on in A-share market. It has 20% risen by for 4 consecutive . The stock price rose from 11.55 yuan to 28 yuan within 5 trading days, with an increase of 116%.
stock price has a 20% stock price. After four consecutive daily limit increases, has its stock price increased by 80%?
is not, but the increase reached 116%. What is more interesting is that among the four consecutive daily limit increases, three quantitative funds have relatively large trading volumes. Judging from the four consecutive daily limit increases, the average yields of these quantitative funds are quite rich.
Is this interesting? What is the name of this stock ?
This stock is called Xuantai Pharmaceutical.
The stock price of Xuantai Pharmaceutical is 25.52 yuan, its increase is 3.7%, the transaction amount reaches 381 million yuan, its total share capital is 453 million yuan, and its circulating share capital is 40.91 million yuan.
's total market value is 10.80 billion, and 's circulating market value is 974 million.
His phased dynamic price-to-earnings ratio is 76.57 times.
financing balance is 29.8793 million yuan, and the margin trading balance is 37.5824 million yuan.
Xuantai Pharmaceutical is a second-new stock listed in August 2022. After
was launched, its market price performed relatively smoothly. At , which was continuous, , trading sideways for about 11.00 yuan, the time for sideways reached five months.
From a technical point of view, after he built a less standard w pattern at the relative bottom, he became a key variety in the market under the hot speculation of related concepts. He experienced four consecutive daily limit increases, and the amplitude of each daily limit was 20%, and the increase in the four trading days reached 106.00%.
has attracted high attention from the market and is also amazing.
Xuantai Medicine has relatively more concepts.
He has the concept of local state-owned enterprises, Science and Technology Innovation Board new stocks, Biomedical , and especially Ursodeoxycholic acid .
has become one of the key concepts of hot speculation in the market.
And Xuantai Pharmaceutical is a real leader in this concept, and the stock price has risen sharply.
From the perspective of the company's operating performance, it has maintained a certain growth in recent years. The total operating income in 2019 was 139 million yuan, and increased by 126.68% year-on-year.
The total operating revenue in 2020 was 319 million yuan, an increase of 129.84% year-on-year.
has achieved high growth for two consecutive years.
However, the total operating income in 2022 was 316 million yuan, a year-on-year decrease of 1.16%.
There is a certain fluctuation with the operating income of the company. The relatively large contrast is that the operating profit of the company has shown continuous high growth.
's profit in 2019 was 4.638 million yuan, an increase of 112.38% year-on-year.
's profit in 2020 was 123 million yuan, a year-on-year increase of 2558.16%.
's operating profit in 2021 was 134.9 million yuan, a year-on-year increase of 9.42%.
ROI has also maintained a good level in the past two years.
The return on equity in 2020 is 25.13%, and the return on equity in 2021 is 21.22%.
enterprises have achieved good economic benefits, one of the important reasons is that the gross profit margin of sales is relatively high.
's gross profit margin in 2019 was 62.05%, and the gross profit margin in 2020 was 81.52%.
's gross sales profit margin in 2021 reached 78.13%.
Its earnings per share also showed corresponding growth.
Earnings per share in 2020 were 0.30 yuan, and Earnings per share in 2021 was 0.33 yuan, a year-on-year increase of 10.00%.
The top ten circulating shareholders hold a total of 4.77 million shares, accounting for 11.65% of the circulating shares.
Since it is a new stock that has been listed for a short time, there are more shares among its major shareholders, which is temporarily locked.
The pharmaceutical sector is a phased market hotspot, especially the key varieties related to the treatment of new coronary pneumonia , which has attracted continuous tracking and pursuit of the market.
Xuantai Pharmaceutical has been explored by the market because of its relatively pure concept of Xiong Deoxygen Mountain, and has attracted market hype and sought after. The stock price in
4 trading days successfully doubled.
What is more interesting is that there are three quantitative investment funds that are continuously tracking, and the total transaction volume is close to about 32% of the total market.
is relatively large in terms of the amount of buying or selling.
has increased by more than 100% due to the increase in stock prices.
Therefore, quantitative investment funds have also obtained correspondingly high returns.
In the medium and long term, although the simple hype concept has won a continuous and rapid rise within a period of time.
However, it also has certain unsustainability.
has corresponding risks of investment hype.
has relatively large returns in the short term, achieving a profit of 116% in 5 trading days.
What do you think about this situation?
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-